Doctor Qidi Ying
Ningbo NO2 Hospital, Ningbo (China)
PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Event: ESC Congress 2021 - The Digital Experience
Topic: Lipid-Lowering Agents
Session: Congress committee e-posters choice in pharmacology and pharmacotherapy
ESC 365 is supported by
